Author
Curran Michael A
Bio: Curran Michael A is an academic researcher from University of Texas System. The author has contributed to research in topics: Interferon & Stimulator of interferon genes. The author has an hindex of 1, co-authored 4 publications receiving 7 citations.
Papers
More filters
Patent•
02 Mar 2021TL;DR: In this article, cyclic dinucleotide compounds and compositions and their application as pharmaceuticals for the treatment of disease are presented and evaluated. But they are not suitable for use as vaccine adjuvants.
Abstract: Disclosed herein are new cyclic dinucleotide compounds and compositions and their application as pharmaceuticals for the treatment of disease. Methods of modulation of immune response to disease, and induce Stimulator of Interferon Genes (STING) dependent type I interferon production and co-regulated genes in a human or animal subject are also provided for the treatment diseases such as cancer, particularly metastatic solid tumors and lymphomas, inflammation, allergic and autoimmune disease, infectious disease, and for use as anti-viral agents and vaccine adjuvants.
7 citations
Patent•
17 Sep 2020TL;DR: The present disclosure is directed to bispecific antibodies which bind to both PD-L1 and L2, and methods of using such antibodies to treat cancers, such as those that express or overexpress PDL1, PDL2, or both.
Abstract: The present disclosure is directed to bispecific antibodies which bind to both PD-L1 and PD-L2, and methods of using such antibodies to treat cancers, such as those that express or overexpress PD-L1, PD-L2, or both.
Patent•
26 Sep 2019
TL;DR: The present disclosure is directed to antibodies binding to PD-L2 and methods of using such antibodies to treat cancers, such as those that express or overexpress it as mentioned in this paper.
Abstract: The present disclosure is directed to antibodies binding to PD-L2 and methods of using such antibodies to treat cancers, such as those that express or overexpress PD-L2.
Patent•
10 Oct 2018TL;DR: The present disclosure is directed to antibodies binding to PD-L1 and methods of using such antibodies to treat cancers, such as those that express or overexpress it.
Abstract: The present disclosure is directed to antibodies binding to PD-L1 and methods of using such antibodies to treat cancers, such as those that express or overexpress PD-L1.
Cited by
More filters
Patent•
17 Mar 2017TL;DR: In this article, cyclic-di-nucleotide cGAMP analogs, methods of synthesizing the compounds, pharmaceutical compositions comprising the compounds thereof, and use of compounds and compositions in medical therapy are discussed.
Abstract: Disclosed are cyclic-di-nucleotide cGAMP analogs, methods of synthesizing the compounds, pharmaceutical compositions comprising the compounds thereof, and use of compounds and compositions in medical therapy.
57 citations
Patent•
06 Jul 2017
TL;DR: In this article, the authors describe compounds and compositions for the induction of expression of a pattern recognition receptor (e.g., STING) and methods of use thereof, and propose a method of using STING for pattern recognition.
Abstract: This invention relates to compounds and compositions for the induction of expression of a pattern recognition receptor (e.g., STING) and methods of use thereof.
21 citations
TL;DR: In this article, the authors evaluate the activity of 3,3'-c-di(2'F,2dAMP) and its phosphorothioate analogues against five STING allelic forms in reporter-cell-based assays and rationalize their findings with X-ray crystallography and quantum mechanics/molecular mechanics calculations.
Abstract: Cyclic dinucleotides (CDNs) are second messengers that bind to the stimulator of interferon genes (STING) and trigger the expression of type I interferons and proinflammatory cytokines. Here we evaluate the activity of 3',3'-c-di(2'F,2'dAMP) and its phosphorothioate analogues against five STING allelic forms in reporter-cell-based assays and rationalize our findings with X-ray crystallography and quantum mechanics/molecular mechanics calculations. We show that the presence of fluorine in the 2' position of 3',3'-c-di(2'F,2'dAMP) improves its activity not only against the wild type (WT) but also against REF and Q STING. Additionally, we describe the synthesis of the acyloxymethyl and isopropyloxycarbonyl phosphoester prodrugs of CDNs. Masking the negative charges of the CDNs results in an up to a 1000-fold improvement of the activities of the prodrugs relative to those of their parent CDNs. Finally, the uptake and intracellular cleavage of pivaloyloxymethyl prodrugs to the parent CDN is rapid, reaching a peak intracellular concentration within 2 h.
16 citations
Patent•
23 Oct 2018
TL;DR: In this article, the compositions of conjugates comprising immune-modulatory agents are also provided, including methods for treating disorders, such as cancer and fibrosis, as well as methods of preparation and use of the conjugate.
Abstract: Various compositions are disclosed. The compositions of conjugates comprising immune-modulatory agents are also provided. Additionally provided are the methods of preparation and use of the conjugates. This includes methods for treating disorders, such as cancer and fibrosis.
12 citations
TL;DR: The cGAS-STING pathway and STing agonists that are in the clinical and preclinical studies are reviewed, recently disclosed patent applications and published journal articles in the field are summarized and both cyclic dinucleotide analogs and non-nucleic acid derived STING agonists are covered.
Abstract: Recent regulatory approval of several immune checkpoint inhibitors has ushered in a new era of cancer immunotherapies with the promise of achieving a durable response. This represents a paradigm shift in cancer treatment from directly targeting tumor cells to harnessing the power of a patient's own immune system to destroy them. The cGAS-STING pathway is the major cytosolic dsDNA sensing pathway that plays a pivotal role in the innate antitumor immune response. With a fundamentally different mode of action (MOA) than immune checkpoint modulators, STING activation can potentially enhance tumor immunogenicity and improve patient responses as a single agent or by synergizing with existing anti-cancer drugs. Therefore, there has been intense interest from the pharmaceutical industry and academic institutions in the search for potent STING agonists as immunotherapies in oncology. In this article, we review briefly the cGAS-STING pathway and STING agonists that are in the clinical and preclinical studies, summarize recently disclosed patent applications and published journal articles in the field and cover both cyclic dinucleotide (CDN) analogs and non-nucleic acid derived STING agonists.
11 citations